There is a growing demand for more patient-centric drug delivery and improved health-care cost management via self-administration and smart devices. The global drug device combination market is projected to reach nearly US$140m by 2025. It’s where the two different worlds of pharmaceutical (GMP) and standardised medical devices collide.Each needs to learn from the other in order to facilitate the regulation process in Europe.
A grey zone in regulation
BackgroundThere is a growing demand for more patient-centric drug delivery and improved health-care cost management via self-administration and smart devices. The global drug device combination market is projected to reach nearly US$140m by 2025. It’s where the two different worlds of pharmaceutical (GMP) and standardised medical devices collide.Each needs to learn from the other in order to facilitate the regulation process in Europe.
Dutch-Italian team improves retinal gene therapy
Latest NewsResearchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors.
Bionure appoints Dr. Lucia Septien as CMO
AppointmentsBionure, a biotech company specialized in neuroprotection, today announces that it has appointed Dr. Lucia Septien as chief medical officer.
Mobidiag secures €25m loan from EIB
Latest NewsMolecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases.
Philogen SpA raises €62m to push registration
Latest NewsPrivately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured €62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III products.
Immunocore appoints Mohammed Dar
AppointmentsImmunocore has appointed Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer. Mohammed Dar will lead the continued clinical development of tebentafusp(IMCgp100) and other key programmes in Immunocore’s pipeline.
Halt of Polyphor trial shrinks company valuation
Latest NewsRoche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).
Dr Stuart Quin appointed as CEO of Medica Group
AppointmentsMedica Group Plc (LSE:MGP) announces that Dr Stuart Quin has been appointed as Chief Executive Officer. Dr Quin will join Medica and its Board of Directors on 1 September 2019. John Graham will remain as Chief Executive Officer until Dr Quin joins the company.
Ethics Council calls for moratorium of clinical germline manipulation
Latest NewsFollowing the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.
BioNtech aquires antibody assets from MabVax Therapeutics
Latest News